- Home
- SDA vs REPL Comparison
SDA vs REPL Comparison
Compare SDA & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDA
- REPL
- Stock Information
- Founded
- SDA 2007
- REPL 2015
- Country
- SDA China
- REPL United States
- Employees
- SDA N/A
- REPL N/A
- Industry
- SDA Blank Checks
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- SDA Finance
- REPL Health Care
- Exchange
- SDA Nasdaq
- REPL Nasdaq
- Market Cap
- SDA 969.0M
- REPL 780.3M
- IPO Year
- SDA N/A
- REPL 2018
- Fundamental
- Price
- SDA $9.42
- REPL $10.14
- Analyst Decision
- SDA
- REPL Strong Buy
- Analyst Count
- SDA 0
- REPL 6
- Target Price
- SDA N/A
- REPL $17.50
- AVG Volume (30 Days)
- SDA 491.9K
- REPL 794.9K
- Earning Date
- SDA 09-16-2024
- REPL 02-06-2025
- Dividend Yield
- SDA N/A
- REPL N/A
- EPS Growth
- SDA N/A
- REPL N/A
- EPS
- SDA N/A
- REPL N/A
- Revenue
- SDA $407,454,000.00
- REPL N/A
- Revenue This Year
- SDA $26.41
- REPL N/A
- Revenue Next Year
- SDA N/A
- REPL $300.41
- P/E Ratio
- SDA N/A
- REPL N/A
- Revenue Growth
- SDA 28.51
- REPL N/A
- 52 Week Low
- SDA $5.71
- REPL $4.92
- 52 Week High
- SDA $11.74
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- SDA 50.48
- REPL 32.06
- Support Level
- SDA $8.96
- REPL $10.00
- Resistance Level
- SDA $10.11
- REPL $11.20
- Average True Range (ATR)
- SDA 0.70
- REPL 0.84
- MACD
- SDA 0.06
- REPL -0.20
- Stochastic Oscillator
- SDA 42.62
- REPL 3.93
About SDA SunCar Technology Group Inc.
SunCar Technology Group Inc is a provider of digitalized enterprise automotive after-sales services and online auto insurance intermediation service in China. It operates an automotive after-sales services business through offering customized service solutions to enterprise clients, who are major banks, insurance companies, telecommunication companies, new energy vehicle, original equipment manufacturers or any client who have end customers demanding automotive services.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.